- |||||||||| Rupex (rupatadine) / Incepta Pharma, Medexus
Targeting PAF in allergic rhinitis: a responder analysis to rupatadine () - May 30, 2021 - Abstract #EAACI2021EAACI_1819; The dosage strategy adjusted by body weight in children 2-11 years old (2.5 mL if weight 10-25 kg, and 5 mL if ≥ 25 kg) provides similar exposure between the two groups of age, and to that obtained in adults with the 10 mg dose tablet formulation. Sponsored by Uriach
- |||||||||| Rupex (rupatadine) / Incepta Pharma, Medexus
Yes!!!!! Rupatadine (Twitter) - Apr 28, 2021
- |||||||||| celecoxib oral / Generic mfg.
Patch testing in fixed drug eruptions: a 10-year retrospective study () - Apr 20, 2021 - Abstract #EAACI2021EAACI_837; Patch tests on residual lesions were reactive already at D1 in 17 patients (42.5%), almost all (14) to NSAIDs (etoricoxib 7, nimesulide 3, celecoxib 1, etodolac 1, ibuprofen 1, tenoxicam 1), 2 to metamizole and 1 to the antihistamine rupatadine...In this study, with 42.5% of positive tests, we confirmed that patch testing is a simple and safe method and can help identify the culprits(s), although this is much dependent on the responsible drug. Culprits have changed over time in our Department with etoricoxib replacing piroxicam, the most frequent drug in the previous decade.
- |||||||||| Rupex (rupatadine) / Incepta Pharma, Medexus, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Journal: Premedication with Montelukast and Rupatadine Decreased Rituximab Infusion Time, Rate, Severity of Reactions, and Use of Rescue Medications. (Pubmed Central) - Apr 10, 2021 The median number of rescue medications was 3 in the SP group and 0 in all other groups. In conclusion, montelukast and rupatadine significantly improved rituximab delivery, decreased the rate and severity of IRs, and reduced the need for rescue medications.
- |||||||||| Rupex (rupatadine) / Incepta
Preclinical, Journal: H1-antihistamines as antischistosomal drugs: in vitro and in vivo studies. (Pubmed Central) - Feb 2, 2021 Although the worm burden reductions achieved are all only moderate, comparatively, treatment with any of the three antihistamines is more effective in early infection than praziquantel. On the other hand, the clinical use of H1-antihistamines for the treatment of schistosomiasis is highly unlikely.
- |||||||||| Rupex (rupatadine) / Incepta
Review, Journal: COVID-19, microthromboses, inflammation, and platelet activating factor. (Pubmed Central) - Jan 5, 2021 The histamine-1 receptor antagonist rupatadine was developed to have anti-PAF activity, and also inhibits activation of human mast cells in response to PAF. Rupatadine could be repurposed for COVID-19 prophylaxis alone or together with other PAF-inhibitors of natural origin such as the flavonoids quercetin and luteolin, which have antiviral, anti-inflammatory, and anti-PAF actions.
- |||||||||| Rupex (rupatadine) / Incepta
Journal: Coronavirus 2019, Microthromboses, and Platelet Activating Factor. (Pubmed Central) - Nov 26, 2020 The histamine receptor antagonist rupatadine was developed to have anti-PAF activity and inhibits activation of human mast cells in response to PAF. Rupatadine could be repurposed for COVID-19 prophylaxis.
- |||||||||| Rupex (rupatadine) / Incepta
Journal: COVID-19 and Multisystem Inflammatory Syndrome, or is it mast cell activation syndrome? (Pubmed Central) - Nov 18, 2020 Hence, the possibility of MCAS should be evaluated in any patient with MIS and/or multisystem inflammatory symptoms. In either case, these syndromes should be addressed with liposomal formulation (in olive pomace oil) of the flavone luteolin (e.g. PureLut® or FibroProtek®) together with the antihistamine rupatadine, which also has anti-platelet activating factor (PAF) activity and inhibits mast cells that have been implicated in the pathogenesis of cytokine storms in COVID-19.
- |||||||||| levocetirizine / Generic mfg.
Clinical, Journal: Cardiac safety of second-generation H -antihistamines when updosed in chronic spontaneous urticaria. (Pubmed Central) - Sep 21, 2020 Blockade of these channels causes QT prolongation leading to torsade de pointes that may possibly degenerate into ventricular fibrillation and sudden death. We considered in detail bilastine, cetirizine, levocetirizine, ebastine, fexofenadine, loratadine, desloratadine, mizolastine and rupatadine and conclude that all these drugs have an excellent safety profile with no evidence of cardiotoxicity even when updosed up to four times their standard licensed dose, provided that the prescribers carefully consider and rule out potential risk factors for cardiotoxicity, such as the presence of inherited long QT syndrome, older age, cardiovascular disorders, hypokalemia and hypomagnesemia, or the use of drugs that either have direct QT prolonging effects or inhibit sgAH metabolism.
- |||||||||| Rupex (rupatadine) / Incepta
Clinical, Clinical Trial,Phase III, Journal: USEFULNESS OF RUPATADINE FOR PRURITUS OF PATIENTS WITH ATOPIC DERMATITIS (Pubmed Central) - Aug 14, 2020 We considered in detail bilastine, cetirizine, levocetirizine, ebastine, fexofenadine, loratadine, desloratadine, mizolastine and rupatadine and conclude that all these drugs have an excellent safety profile with no evidence of cardiotoxicity even when updosed up to four times their standard licensed dose, provided that the prescribers carefully consider and rule out potential risk factors for cardiotoxicity, such as the presence of inherited long QT syndrome, older age, cardiovascular disorders, hypokalemia and hypomagnesemia, or the use of drugs that either have direct QT prolonging effects or inhibit sgAH metabolism. These results suggest the long-term usefulness of rupatadine for pruritus in AD.
- |||||||||| Rupex (rupatadine) / Incepta, levocetirizine / Generic mfg., desloratadine / Kaken, Incepta, Merck (MSD), Generic mfg.
Journal: Route to Prolonged Residence Time at the Histamine H Receptor: Growing from Desloratadine to Rupatadine. (Pubmed Central) - Jun 18, 2020 However, cycloaliphatic substituents directly attached to the piperidine amine (i.e., lacking the spacer) have decreased binding affinity and residence time compared to their methylene-linked structural analogues. Guided by docking studies, steric constraints within the binding pocket are hypothesized to explain the observed differences in affinity and binding kinetics between analogues.
- |||||||||| Rupex (rupatadine) / Incepta
Clinical, Journal: A preliminary study on efficacy of rupatadine for the treatment of acute dengue infection. (Pubmed Central) - Oct 31, 2019 Although the primary end-point of a significant reduction in fluid leakage (development of pleural effusions or ascites) was not met, post-hoc analyses revealed small but significant differences in several parameters on individual illness days - higher platelet counts and lower aspartate-aminotransferase levels on day 7 in the rupatadine group compared to the placebo group, and smaller effusions on day 8 in the subgroup of patients with pleural effusions. However, due to the small sample size and range of recruitment time, the potential beneficial effects of rupatadine require further evaluation in large studies focused on recruitment during the early febrile phase.
- |||||||||| Rupex (rupatadine) / Incepta Pharma, Medexus
Trial termination: Chronic Urticaria - Long Term Assessment of Effects of Rupatadine (clinicaltrials.gov) - Sep 17, 2019 P3, N=192, Terminated, Rupatadine promoted higher proportions of responders according to stringent response criteria and in a dose-dependent manner, with faster and higher response rates in the 20 mg group. Recruiting --> Terminated; poor recruitment
- |||||||||| Rupex (rupatadine) / Incepta
Clinical, Review, Journal: Platelet-Activating Factor (PAF) in Allergic Rhinitis: Clinical and Therapeutic Implications. (Pubmed Central) - Sep 1, 2019 However, rupatadine, a second-generation antihistamine with dual antihistamine and anti-PAF effects has shown promising results by both blocking nasal symptoms and inhibiting mast cell activation induced by PAF, in comparison to antihistamine receptor drugs. In conclusion, the inhibition of PAF may be an interesting approach in the treatment of allergic rhinitis as part of a global strategy directed at blocking as many relevant inflammatory mediators as possible.
- |||||||||| Rupex (rupatadine) / Incepta
Rupatadine too! (Twitter) - Apr 23, 2019
|